Hereditary Angioedema Clinical Trials

213 clinical trials for Hereditary Angioedema across international registries, including 32 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema — RECRUITING · PHASE3
• Donidalorsen Treatment in Children With Hereditary Angioedema — RECRUITING · PHASE3
• A Long-Term Study of Navenibart in Participants With Hereditary Angioedema — RECRUITING · PHASE3
• Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema — RECRUITING · PHASE2
• A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE — RECRUITING · PHASE3
• STOP-HAE: A Phase 3 Study of ADX-324 in HAE — RECRUITING · PHASE3
• Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) — RECRUITING · PHASE3
• A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema — RECRUITING · PHASE3
• A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema — RECRUITING · NA
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia — RECRUITING
• Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — RECRUITING · PHASE3
• Institutional Registry of Rare Diseases — RECRUITING
• Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies — RECRUITING · PHASE3
• Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 — RECRUITING
• PHASE 3 TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF NAVENIBART IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA – ORBIT-EXPANSE — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SIRNA TARGETING OF PREKALLIKREIN WITH ADX-324 IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA — RECRUITING · PHASE3
• Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients — RECRUITING · PHASE1
• POST STUDY ACCESS OF CSL312 (GARADACIMAB) FOR THE ROUTINE PREVENTION OF HAE ATTACKS IN PEDIATRIC PARTICIPANTS (2-11 YEARS OLD) WITH HEREDITARY ANGIOEDEMA (HAE) WHO HAVE COMPLETED CSL312_3003 STUDY — RECRUITING
• PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NAVENIBART IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA ¿ ALPHA-ORBIT — RECRUITING · PHASE3
• A PHASE 4 OPEN-LABEL STUDY TO EVALUATE THE SAFETY AFTER SWITCHING TO CSL312 (GARADACIMAB) FROM CURRENT PROPHYLACTIC HAE TREATMENT IN SUBJECTS WITH HAE ¿ 12 YEARS OF AGE — RECRUITING · PHASE4
• HAELO: A PHASE 3, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NTLA-2002 IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA — RECRUITING · PHASE3
• A LONG-TERM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED DEUCRICTIBANT EXTENDED-RELEASE TABLET FOR PROPHYLAXIS AGAINST ANGIOEDEMA ATTACKS IN ADOLESCENTS AND ADULTS WITH HEREDITARY ANGIOEDEMA — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED DEUCRICTIBANT EXTENDED-RELEASE TABLET FOR PROPHYLAXIS AGAINST ANGIOEDEMA ATTACKS IN ADOLESCENTS AND ADULTS WITH HEREDITARY ANGIOEDEMA — RECRUITING · PHASE3
• A PHASE 2 LONG-TERM OPEN-LABEL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF REPEAT DOSING OF STAR-0215 IN ADULT PATIENTS WITH HEREDITARY ANGIOEDEMA (THE ALPHA-SOLAR TRIAL) — RECRUITING · PHASE2
• A PHASE 3 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CSL312 (GARADACIMAB) IN THE PROPHYLACTIC TREATMENT OF HEREDITARY ANGIOEDEMA IN PEDIATRIC SUBJECTS 2 TO 11 YEARS OF AGE — RECRUITING · PHASE3
• A PHASE II/III, EXTENSION STUDY OF ORALLY ADMINISTERED PHA-022121 FOR ACUTE TREATMENT OF ANGIOEDEMA ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA — RECRUITING · PHASE2
• AN OPEN-LABEL, LONG TERM SAFETY AND EFFICACY STUDY OF DONIDALORSEN IN THE PROPHYLACTIC TREATMENT OF HEREDITARY ANGIOEDEMA (HAE) — RECRUITING
• A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA (HAE) WHO ARE 2 TO < 12 YEARS OF AGE — RECRUITING · PHASE3
• AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CSL312 (GARADACIMAB) IN THE PROPHYLACTIC TREATMENT OF HEREDITARY ANGIOEDEMA — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE LEVELS OF BCX7353 AS AN ORAL TREATMENT FOR THE PREVENTION OF ATTACKS IN SUBJECTS WITH HEREDITARY ANGIOEDEMA — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-PERIOD, THREE-SEQUENCE, PARTIAL CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF 2000 IU OF C1 ESTERASE INHIBITOR [HUMAN] LIQUID FOR INJECTION FOR THE PREVENTION OF ANGIOEDEMA ATTACKS IN ADOLESCENTS AND ADULTS WITH HEREDITARY ANGIOEDEMA — RECRUITING · PHASE3
• HELP STUDY: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE DX-2930 FOR LONG-TERM PROPHYLAXIS AGAINST ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) — RECRUITING
• Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency. — ACTIVE_NOT_RECRUITING · PHASE3
• Efficacy and safety study to evaluate DX-2930 in preventing agioedema attacks in patients with Type I and Type II heriditary angioedema (HAE) — COMPLETED · PHASE3
• A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects with Hereditary Angioedema — TERMINATED · PHASE2
• EAP for Deucrictibant Immediate-release — OTHER
• A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema — COMPLETED
• Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema — OTHER
• A Phase 3 Study to Evaluate the Safety and Pharmacokinetics of Berotralstat Prophylaxis in Children with Hereditary Angioedema (HAE) Who Are 2 To < 12 Years of Age. — TERMINATED · PHASE3
• Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II — COMPLETED · PHASE3
• A Survey of Lanadelumab in Participants With Hereditary Angioedema — ACTIVE_NOT_RECRUITING
• A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema — NOT_YET_RECRUITING · PHASE3
• HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — ACTIVE_NOT_RECRUITING · PHASE3
• Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab — COMPLETED · PHASE4
• Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat — OTHER
• An open-label study to provide berotralstat access to subjects with type I and II hereditary angioedema who were previously enrolled in berotralstat studies — TERMINATED · PHASE3
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema — OTHER · PHASE3
• Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) — NOT_YET_RECRUITING · PHASE4
• A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients with Hereditary Angioedema (The ALPHA-SOLAR Trial) — TERMINATED · PHASE2
• STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema — TERMINATED · PHASE3

Refine this search